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Abstract
Hyaluronic acid (HA), as one of the main components of the extracellular matrix (ECM), plays a significant role 
in a multitude of biological processes involving cell migration, proliferation, differentiation, wound healing 
and inflammation. Thanks to its excellent biocompatibility, biodegradability and hygroscopic properties, HA 
has been used in its natural form for joint lubrication and ocular treatment. The chemical structure of HA 
can be easily modified by direct reaction with its carboxyl and hydroxyl groups. Recently, HA derivatives 
have been synthesised with the aim of developing HA-based materials with increased mechanical strength, 
improved cell interactions and reduced biodegradation and studied for regenerative medicine purposes, 
including cell therapy and tissue engineering. In this context, the present manuscript reviews HA applications 
from a basic point of view – including chemical modifications and cellular biology aspects related to clinical 
translation – and future perspectives of using biofabrication technologies for regenerative medicine. A detailed 
description of current clinical trials, testing advanced therapies based on combination of stem cells and HA 
formulations, is included. The final goal was to offer an integral portrait and a deeper comprehension of the 
current applications of HA from bench to bedside.
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List of Abbreviations
2D   two dimensional
3D   three dimensional
Ad  adamantane
BDDE  butanediol-diglycidyl ether
BDNF  brain-derived neurotrophic factor
BM   bone marrow
BMAC   BM aspirate concentrate
BMC   bone marrow concentrate
CD   β-cyclodextrin
CDCs   cardiosphere-derived cells
DEO   1,2,7,8-diepoxyoctane
DM   diabetes mellitus
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DVS  divinylsulphone
ECM  extracellular matrix
EDC  1-ethyl-3-[3-(dimethylamino)-
   propyl]-carbodiimide
EPCs  endothelial progenitor cells
eEPCs  embryonic EPCs
EX 810  ethylene glycol diglycidyl ether
FDA  Food and Drug Administration
FN  fibronectin
GH  guest-host
GlcA  glucuronic acid
GlcNAc N-acetyl-D-glucosamine
HA  hyaluronic acid
HAMC  hyaluronan and methylcellulose
HAS  hyaluronic acid synthases
HEMA  hydroxyethylmethacrylate
IA   intra articular
ICOAP  intermittent and constant pain score
IKVAV  isoleucine-lysine-valine-alanine-
   valine
IVD  intervertebral disc
LME  L-leucine methyl ester
MeHA  methacrylated HA
MI   myocardial infarction
MPCs  mesenchymal precursor cells
MSCs  mesenchymal stem cell
N/P  not provided
NSCs  neural stem and progenitor cells
OA  osteoarthritis
PBS  phosphate buffered saline
PBSCs  peripheral blood stem cells
PEDOT  poly 3,4-ethylenedioxythiophene
PEG  polyethylene glycol
PCL  poly(ε-caprolactone)
PLA  poly(D,L-lactic acid)
PLGA  poly(D,L-lactic-co-glycolic acid)
PRP  platelet-rich plasma
RA  rheumatoid arthritis
RGD  arginine-glycine-aspartic acid
rhBMP-2 human bone morphogenetic
   protein-2
RPCs  retinal progenitor cells
SDF-1α  recombinant stromal cell derived
   factor-1 alpha
SFF  solid freeform fabrication
TE   tissue engineering
TEHV  tissue engineered heart valves
UC-MSCs umbilical cord MSCs
UCB-MSCs umbilical cord blood-derived MSCs
VAS  visual analogue scale
VICs  valvular interstitial cells
WOMAC Western Ontario and McMaster
   Universities Arthritis Index
Introduction
In recent decades, there has been an increasing interest 
in the development of regenerative approaches to 
repair or replace damaged tissues. Additionally, 
the continued development of several therapeutic 
strategies demands the use of more effective, 
biocompatible and bio-functional materials. In 
this sense, HA and its derivatives have been 
positioned as one of the most suitable and widely 
used compounds for biomedical applications. HA, 
being the main component of the ECM (Fraser et 
al., 1997), presents unique characteristics for its use 
in regenerative medicine. It is also involved in a 
large number of relevant biological functions in the 
human body, such as wound healing (Li et al., 2018), 
inflammation (Chan et al., 2015), cell proliferation and 
migration (Murakami et al., 2018), embryogenesis, 
morphogenesis (Toole, 1997) and angiogenesis (Silva 
et al., 2016).
 Thanks to its biocompatibility, biodegradability, 
mucoadhesive and hydrophilic properties, HA 
has been successfully applied in a broad range of 
cosmetics, drugs and medical devices. Moreover, 
changes of HA concentration are associated with 
many diseases. Consequently, HA concentration 
has been analysed in blood, body fluids or tissues as 
a diagnostic marker of diseases such as rheumatoid 
arthritis (Niki et al., 2012) and liver pathologies 
(Gudowska et al., 2017).
 HA is also used for supplementation of joint fluid 
(Wu et al., 2017), eye surgery (Durrie et al., 2018), wound 
healing (Simman et al., 2018), cosmetic regeneration 
and reconstruction of soft tissues (Geronemus et al., 
2017). HA is degraded by hyaluronidase and/or by 
reactive oxygen/nitrogen species that are generated 
during tissue inflammation, inflammatory response 
in sepsis or ischaemia-reperfusion injury (Valachová 
et al., 2015; Valachová et al., 2016). Therefore, the 
poor mechanical properties, rapid degradation and 
clearance in vivo without crosslinking limit HA 
clinical applications (Wende et al., 2016). Scaffolds 
for regenerative medicine application should be 
degraded over the course of tissue regeneration to 
allow complete repair by the host tissue. Controlling 
the degradation rate of an HA-based hydrogel is 
still a challenge for its applications in TE. It is of 
great interest to cross-link HA into an hydrogel or 
to modify it chemically for improving mechanical 
properties and controlling residence time (i.e. 
controlled degradation, metabolism and clearance). 
In recent years, HA derivatives, mainly aiming to 
improve their mechanical properties and reduce 
biodegradation, have been extensively studied in cell 
therapy (Smith et al., 2013), drug delivery (Cai et al., 
2017) and TE (Seidlits et al., 2011).
 The purpose of the present review was to highlight 
those medical areas in which HA and its derivatives 
are significantly contributing, including HA medical 
formulations with stem cells that are currently 
being tested for several diseases in clinical trials. 
Additionally, a brief summary of the different HA 
chemical modifications that expand its biomedical 
applications are included. More information as to the 
chemical transformations of HA is included in other 
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publications (Hemshekhar et al., 2016; Highley et al., 
2016; Knopf-Marques et al., 2016; Kuo and Prestwich, 
2011; Prestwich, 2011; Schanté et al., 2011).
HA: description and origin
HA, also called hyaluronan, is one of the ECM 
glycosaminoglycans that exists as protein-free 
unbranched long polysaccharide chains with different 
molecular weights (from 1 kDa up to 8 MDa) and is 
exclusively non-sulphated (Barbucci et al., 2000). The 
backbone is composed of a repeated disaccharide 
unit of D-GlcA linked β(1→3) to GlcNAc. The 
disaccharide units are connected by GlcNAc linked 
β(1→4) to GlcA (Fig. 1) (Furlan et al., 2005; Hargittai 
and Hargittai, 2008; Liu et al., 2011).
 HA is produced in the cytoplasmic membrane of 
mammalian cells, amphibians and bacteria by the 
three HAS membrane enzymes, HAS-1, HAS-2 and 
HAS-3, which differ in their catalytic activities and 
molecular weight of the HA synthesised. HAS-1 is 
responsible for the production of medium to high 
molecular weight HA (200-2000 kDa), HAS-2 for high 
molecular weight HA (2000 kDa) and HAS-3 for low 
molecular weight HA (< 300 kDa) (Itano et al., 1999; 
Lee and Spicer, 2000). HA is continuously extruded 
through the plasma membrane into the ECM where it 
provides a hydrophilic viscous medium that facilitates 
cell motility, proliferation and differentiation (Xu et 
al., 2012). One of the characteristics of HA is its large 
capacity to bind water molecules up to 10,000 times 
its own weight (Laurent, 1992). HA metabolism is 
regulated by its production through the different 
HAS and its degradation in the plasma membrane, 
or in lysosomes, by hyaluronidases to maintain tissue 
physiological concentrations (Khaldoyanidi et al., 
2014). HA is a key component of the ECM, especially 
abundant in connective tissues and present at high 
concentration in the synovial fluid of joints, vitreous 
humour, hyaline cartilage, IVD and umbilical cord 
(Dicker et al., 2014; Knopf-Marques et al., 2016; Toole, 
2004). The major HA receptor is CD44, a cell surface 
glycoprotein involved in cell-cell and cell-matrix 
interactions, which is endogenously expressed at low 
levels in different cell types (Isacke and Yarwood, 
2002). Traditionally, HA has been extracted from 
rooster comb-like animal tissues; however, HA is also 
produced by bacterial fermentation, mainly using 
Streptococcus zooepidemicus, a natural manufacturer 
of HA (de Oliveira et al., 2016; Liu et al., 2011).
HA-derived-biomaterials
Thanks to its high molecular weight and hydrophilic 
nature, the polysaccharidic structure of HA can form 
viscous water solutions that have many interesting 
uses in biomedical applications, mainly as a carrier 
of biological components, such as cells (Kim et 
al., 2017; Prestwich, 2011). Nevertheless, these 
solutions are not designed to withstand time since, 
in biological media, HA is easily degraded and the 
diluted solutions lack sufficient mechanical strength 
to be self-supporting in a particular location over 
prolonged time (Xu et al., 2012). As such, HA has 
been subjected to different chemical modifications 
aimed at expanding its biomedical uses (Prestwich 
et al., 1998; Schanté et al., 2011; Volpi et al., 2009). 
Synthetic transformation has focused on increasing 
its molecular weight to generate novel HA derivatives 
able to produce a more viscous solution or even 
gels that can stay longer in the body and have a 
therapeutic effect. The objective is to modulate the 
material according to a specific application without 
compromising its biocompatibility, biodegradability, 
ability to interact with cells and other living tissue, 
etc.. In this sense, chemical modifications have been 
focused on increasing its mechanical strength and/
or improving cell interactions. With respect to 
increasing HA mechanical strength, two different 
strategies have been applied. The first one implies 
the development of cross-linkable HA derivatives 
through the introduction in the backbone of 
functional groups able to covalently inter-connect HA 
polymer chains (Collins and Birkinshaw, 2008). Such 
modification leads to a cross-linked HA derivative 
with higher molecular weight and lower solubility 
that, in the presence of water, forms a self-supported 
hydrogel (chemical hydrogel) where its rigidity or 
mechanical strength can be regulated by the degree 
of cross-linking (Kim et al., 2017). Alternatively, the 
solubility of HA can also be reduced by introduction 
of hydrophobic groups in its structure. The nature 
of these hydrophobic groups and the degree of HA 
functionalisation are important for the formation of 
amphipathic structures that tend to form aggregates in 
the presence of water, generating physical hydrogels 
(Dicker et al., 2014). Either, hydrophobised or cross-
linkable HA derivatives exhibit higher resistance to 
biodegradation and can be used for cell culture (Aulin 
et al., 2011), viscosupplementation (Adams et al., 1995) 
and as vehicle for in vivo cell (Smith et al., 2013) and 
drug delivery (Cai et al., 2017).
 The chemical structure of HA has three potential 
functional groups that can be easily modified by 
covalent reaction (Fig. 1): the carboxylic acid of the 
Fig. 1. Molecular structure of HA repeating 
disaccharide units composed of D-glucuronic 
acid and N-acetyl-D-glucosamine.
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GlcA unit, the primary hydroxyl group of the GlcNAc 
– although the secondary hydroxyl groups can also 
be reactive – and the amine group of GlcNAc formed 
after a deacetylation reaction (Fakhari and Berkland, 
2013). The hydroxyl groups can be chemically 
modified by formation of an ether or ester linkage, 
while the carboxyl and amine groups can form new 
ester and amide bonds (Khunmanee et al., 2017). 
These HA chemical modifications can also fall into 
two different categories depending if the material can 
be further functionalised or not (Prestwich and Kuo, 
2008). If the material is an end-product that cannot 
be further modified in the presence of a biological 
substrate, it is defined as monolithic. However, if it 
can form new chemical bonds in the presence of a 
biological substrate it is defined as living. These living 
HA derivatives can be used in 3D cell cultures and for 
in vivo cell delivery (Prestwich, 2007). Nevertheless, 
precautions are required to ensure that all the 
chemical reactions are biologically biocompatible and 
do not produce toxic by-products in the short or long 
term.
Monolithic HA derivatives
Primary strategies to originate cross-linkable HA 
derivates are based on the direct cross-link between 
unmodified HA polymer chains by using bi-
functional cross-linker reagents able to react with the 
hydroxyls and the carboxylic acid of the HA backbone 
(Burdick and Prestwich, 2011). This protocol uses 
reaction conditions and reagents incompatible 
with the presence of cells and, therefore, used to 
originate monolithic HA derivates (Prestwich, 2011) 
(Fig. 2). For example, under strong basic conditions, 
hydroxyl groups can also react with divinylsulphone 
and different epoxides, such as bisglycidylepoxides 
(DEO, BDDE) and epichlorohydrin, to form ether 
linkages more stable to hydrolysis (Wende et 
al., 2016). Additionally, HA can also react with 
glutaraldehyde in an acid medium to originate acetal 
or hemiacetal linkages (Khunmanee et al., 2017). In 
this sense, Zhang et al. (2012) developed a composite 
HA-agarose material using epichlorohydrin as a 
cross-linker. One of the advantages of this material 
is that its degradation rates can be controlled. 
In a similar way, Kim et al. (2012) improved the 
mechanical, degradation and biological response 
of an HA-collagen composite hydrogel for cartilage 
regeneration using ethyleneglycoldiglycidyl ether 
as crosslinker agent. With the objective of reducing 
HA degradation rates and modulate hydrogel pore 
sizes, Collins and Birkinshaw (2011) studied a series 
of HA scaffolds obtained by simply solution gelling 
using glutaraldehyde, EX 810, EDC with LME and 
divinylsulphone as cross-linker agents. Results show 
that a suitable soft tissue HA scaffold is obtained 
with the combination of EDC and LME (Collins and 
Birkinshaw, 2011). Lai (2014) studied the amount of 
divinylsulphone covalently incorporated into the HA 
structure and its relationship with mechanical stability 
and resistance against enzymatic degradation of the 
resulting hydrogels. Its cytocompatibility as a matrix 
Fig. 2. Traditional monolithic cross-linked transformation of HA with DVS and BDDE.
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for the growth of retinal pigment epithelial cells was 
also evaluated (Lai, 2014).
 A direct cross-linking reaction between HA 
polymer chains can also be performed with 
carbodiimides, usually, EDC. The reaction proceeds 
through activation of the carboxylic acid by EDC to 
give acylisourea active ester that reacts with nearby 
hydroxyls generating intermolecular cross-links (Fig. 
3). This reaction proceeds under mild conditions 
at neutral pH and it is compatible with biological 
macromolecules that can be easily degraded. HA is 
cross-linked with collagen to enhance its mechanical 
stability and to improve its biological compatibility 
(Davidenko et al., 2010; Wang and Spector, 2009). 
These scaffolds promote angiogenesis (Perng et 
al., 2011); in addition, the biological performance 
of HA-gelatine scaffolds of tuneable porosity was 
studied in the presence of L929 fibroblasts, showing 
no cytotoxicity (Zhang et al., 2011a). Films composed 
of HA-carboxymethylcellulose (Seprafilm®, Sanofi-
Aventis U.S. LLC, Bridgewater, NJ, USA) used as 
adhesion barrier mainly for abdominal or pelvic 
laparotomy are chemically produced by EDC cross-
linking reaction (Schneider et al., 2007).
Living HA derivatives
More recently, the focus has been centred on 
the development of HA derivatives able to form 
hydrogels in the presence of cells under mild 
conditions. These materials offer the advantages of 
originating 3D cell constructs for TE or cell delivery 
(Ruel-Gariépy and Leroux, 2004). Normally, HA is 
chemically modified to originate a derivative that can 
generate the hydrogel in a biological environment 
by a cross-linking reaction that proceeds under 
physiological conditions without generating any 
toxic by-products (Khunmanee et al., 2017). One of 
the first examples is the coupling of HA with adipic 
dihydrazine. The reaction proceeds under mild 
conditions to originate an HA hydrazone derivative 
stable under physiological conditions that can easily 
react with aldehyde crosslinking agents through its 
hydrazine group in the presence of cells (Prestwich 
et al., 1998; Zhang et al., 2010) (Fig. 4). These HA 
hydrazone derivatives were coupled with different 
aldehydes, such as poly(ethylene) glycol aldehyde 
(Kirker et al., 2002) and genipin (Zhang et al., 2010) 
to originate materials suitable for TE applications.
 Thiol chemistry based on the formation of 
disulphide bonds or nucleophilic attachment of thiol 
groups under mild conditions is also compatible 
with physiological conditions. Shu et al. (2002; 
2006) developed an HA derivative using hydrazide 
reagents containing a disulphide bond. After cleavage 
of the disulphide bond and the formation of thiol 
groups, slow formation of crosslinks in the presence 
of air takes place (Fig. 5).
 Gramlich et al. (2013) described the functionalisation 
of the HA with norbonene groups. This derivative 
can cross-link under mild conditions by a thiol-ene 
reaction to produce hydrogels with controllable 
mechanical properties. HA hydrogels that are formed 
by an enzymatic reaction were also developed 
by Kurisawa et al. (2005). HA functionalised with 
tyramide can rapidly form a hydrogen in the presence 
of H2O2 and horseradish peroxidase. This protocol 
is biocompatible and useful for various applications 
(Kurisawa et al., 2005; Wang et al., 2010). Huisgen 
azide-alkyne 1,3-dipolar cycloaddition, known as 
click chemistry has also been studied for this purpose. 
Huerta-Angeles et al. (2012) described the synthesis of 
HA derivatives having an azide and alkyne groups. 
In the presence of Cu(I) catalyst the reaction proceeds 
under physiological conditions to originate the gel. 
Nevertheless, the presence of the metallic catalyst can 
introduce toxicity to the environment (Crescenzi et 
al., 2007).
Hydrophobic HA derivatives
To originate mechanically stable hydrogels, HA 
has been modified with the intention of increasing 
its hydrophobicity. Examples of these types of 
Fig. 3. Cross-linked HA through activation of the carboxylic acid mediated by EDC.
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Fig. 4. HA hydrazone derivative that allows cross-linking reactions under physiological conditions.
Fig. 5. HA derivative modified with thiol groups for disulphide or thiol-ene cross-linking reaction 
under physiological conditions.
derivatives are HYAFF® (Haemo Pharma GmbH, 
Hornstein, Austria) biomaterials that are the result 
of a partial esterification of HA carboxylates to 
benzylesters (Benedetti et al., 1993) (Fig. 6). The 
degree of esterification modifies the physicochemical 
properties of these materials making them adequate 
for different applications. These hyaluronan esters 
can be easily manipulated to produce membranes 
and fibres, lyophilised to obtain porous materials 
or processed to produce microspheres (Mano et al., 
2007). When the degree of esterification is high, these 
materials are insoluble in water and are used, in solid 
form, as scaffolds for the growth of human fibroblasts, 
chondrocytes and bone-marrow-derived MSCs for 
repair of cartilage and bone defects (Caravaggi et al., 
2003; Lisignoli et al., 2003). Additionally, HYAFF® 
biomaterials in combination with PCL are excellent 
biomaterials for the in vivo regeneration of sheep 
meniscal tissue, where the implants remain in 
position and show excellent tissue ingrowth (Chiari 
et al., 2006). Another example commercially available 
is HYADD®4 (Fidia Pharma USA, Parsippany, 
NJ, USA), derived from the partial amidation of 
HA with hexadecylamine. This derivative forms a 
192 www.ecmjournal.org
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viscoelastic hydrogel that shows an enhancement 
of intra-articular residence time (Mainil-Varlet et al., 
2013; Priano, 2017).
Improving cell interactions of HA derivatives
HA has been covalently modified by the addition 
of biological relevant molecules with the objective 
of mimicking the native tissue environment and 
achieving a controlled and tuneable cell response 
(Lam et al., 2014; Mehra et al., 2006; Zhang et al., 
2011b). Additionally, the coupling of ECM proteins 
also permits the entrapment of antibodies and small 
molecules within the HA hydrogel, improving its 
role as an in vivo carrier. In this context, in order to 
obtain HA materials with cell-attachment properties, 
HA was modified with cell adhesion motifs, such 
as short RGD peptides (Shu et al., 2004), and ECM 
proteins, such as collagen (Mehra et al., 2006), 
laminin (Hou et al., 2005) and fibronectin (Brown 
et al., 2011). Camci-Unal et al. (2010) developed a 
CD34 antibody immobilised on an HA hydrogel for 
selectively captured and spread EPCs. The results 
show that these materials can potentially be used 
to enhance the biocompatibility of implants such as 
artificial heart valves. Kisiel et al. (2013) developed an 
HA hydrogel modified with a stabilised fibronectin 
fragment containing the major integrin-binding 
domain to improve MSC attachment and spreading. 
The in vivo delivery of this HA hydrogel derivative 
containing the rhBMP-2 growth factor results in a 
significant increase in bone formation and a better 
organisation of collagen fibres as compared to the 
non-functionalised HA hydrogel (Kisiel et al., 2013). 
Likewise, the adhesion of glycosaminoglycans such 
as heparin and chondroitin sulphate enables the 
entrapment of growth factors, which also makes HA 
suitable for cell culture and differentiation (Ghosh et 
al., 2006; Hosack et al., 2008; Kontturi et al., 2014; Lu et 
al., 2013; Schanté et al., 2011). Following this strategy, 
Xu et al. (2011) synthesised a heparin-decorated 
HA hydrogel that can bind rhBMP-2 specifically. 
The results show that the controlled release of the 
growth factor, in combination with the inductive role 
of HA in chondrogenesis, leads to efficient in vitro 
differentiation of murine MSCs.
 Additionally to the chemical modifications 
of HA derivatives, there are different processing 
and fabrication techniques for the development of 
structurally tuneable and mechanically suitable 
HA-based materials. Although HA is mainly used 
as an injectable hydrogel, cross-linked HA scaffolds 
can be produced by phase-separation, supercritical 
fluid technology, porogen leaching, freeze-drying 
or emulsion techniques,  whereas fibrous and 
nanofibrous structures are mainly created by 
electrospinning (Ekaputra et al., 2008; Knopf-Marques 
et al., 2016). In addition to the internal architecture 
patterning obtained by these techniques, geometry 
and spatial resolution parameters can be customised 
by other fabrication strategies, such as centrifugal 
casting (Mironov et al., 2005), scaffold templating 
(Ortuño-Lizarán et al., 2016), lithography (Takahashi 
et al., 2009) or 3D printing (Skardal et al., 2010). 
Recently, 3D bioprinting has gained significant 
attention since it allows the creation of scaffolds with 
precise deposition of cells, biomaterials and bioactive 
molecules (referred to as bioinks) in a spatial location 
in order to mimic the native tissue anatomy (Khalil and 
Sun, 2009). The ease of modifying the HA backbone 
with functional groups, such as hydrophobic moieties 
or cross-linkable groups, enables obtaining printable 
hydrogels (Kesti et al., 2015; Loebel et al., 2017). 
Therefore, thanks to the addition of HA, the bioink 
viscosity can be increased to allow for continuous 
extrusion of hydrogel strands (Murphy et al., 2018). 
The most recent attempt is by Loebel et al. (2017), 
who developed a self-assembling HA hydrogel 
based on GH hydrophobic interactions of conjugated 
groups, Ad (guest) and CD (host). The GH hydrogel 
is composed of HA as the polymer backbone, which 
is modified with either the host molecule (CD-HA) 
or the complementary guest molecule (Ad-HA). 
The supramolecular GH associations disassemble 
when ejected through a syringe (shear-thinning) 
and reassemble within seconds (self-healing) upon 
cessation of shear (Loebel et al., 2017).
 Other strategies consisting of adding gelling 
agents, both natural and/or synthetic, have also 
made possible the production of printable HA-based 
hydrogels (Derakhshanfar et al., 2018; Thomas and 
Fig. 6. Partial esterification of HA with benzyl alcohol to originate HYAFF® derivatives.
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Willerth, 2017). An example is the use of crosslinking 
chemistries or gelling components, such as gelatine, 
to obtain HA bioinks with tuneable mechanical 
properties that match the tissue of interest physical 
parameter profiles. Accordingly, Skardal et al. (2010) 
printed HA-gelatine hydrogels through a syringe 
needle into robust structures, followed by a second 
photo-cross-linking step to create a bioprinted 
tubular construct with cells. After the process of 
bioprinting and culture, these cells maintain their 
viability and gradually remodel the synthetic matrix 
to create a natural ECM (Skardal et al., 2010). Other 
combinations such as methacrylated gelatine and 
methacrylated HA modified with hydroxyapatite 
particles have been prepared for the development 
of a bioink for bone tissue engineering. This 
bioink demonstrates its suitability for the build-
up of relevant 3D geometries with microextrusion 
bioprinting and a significant positive effect on bone 
matrix development after 28 d in culture (Wenz 
et al., 2017). Porous constructs through layer-by-
layer deposition of cell-laden material based on 
HA and hydroxyethylmethacrylate derivatised 
dextran or atelocollagen have been evaluated for 
cell viability of encapsulated chondrocytes and 
human MSCs showing excellent cytocompatibility 
(Pescosolido et al., 2011; Shim et al., 2016). However, 
in some cases, the HA bioink is reinforced by double 
printing with a thermoplastic polymer, such as 
PCL (Mouser et al., 2017; Shim et al., 2016; Stichler 
et al., 2017) or PLA (Souness et al., 2018). Park et al. 
(2011) developed scaffolds of HA grafted to PLGA 
incorporating rhBMP-2 by SFF. Results show the 
in vitro enhancement of osteoblast cell growth and 
high gene-expression levels of alkaline phosphatase 
and osteocalcin. Moreover, scaffolds implanted into 
calvarial bone defects of rats reveal effective bone 
regeneration (Park et al., 2011). Efforts have also 
been made to simulate the biochemical profile of the 
scaffold and optimise the bioactivity of the bioink 
by mixing HA derivatives with ECM components 
and tissue-specific growth factors, obtaining a more 
effective tissue regeneration (Shim et al., 2016; Skardal 
et al., 2015).
Therapeutic applications of HA, including 
cell therapy
The success of a cell therapy relies on identifying 
an appropriate cell source as well as a strategy to 
maintain and localise the cells in the desired area 
(López-Ruiz et al., 2016). In this context, stem cells 
and tissue-specific cells were investigated as suitable 
cell sources for the repair of different kinds of tissues 
(Bardelli and Moccetti, 2017). However, current cell 
therapy practice is inefficient since therapeutic cells 
are less integrated into the tissue (Lebaschi et al., 
2017). To improve cell engraftment and survival after 
transplantation, new compounds have been proposed 
as injectable and biological vehicles for delivery. One 
of these new vehicles is HyStem® (BioTime, Inc., 
Alameda, CA, USA), a HA-based material approved 
for cell therapy that is used in combination with 
stem cells (Prestwich et al., 2012). HyStem® can form 
a hydrogel in the presence of cells, using a HA living 
derivative. The cross-linking reaction is mediated by 
a thiol-ene reaction between the reactive thiol groups 
of a thiolated HA and a denatured collagen (Gelin-S, 
BioTime, Inc.) that reacts with polyethylene glycol 
diacrylate (Extralink, BioTime, Inc.) cross-linker 
reagent. Smith et al. (2013), in an in vivo study using 
a mouse model of MI, observed that an injection of 
HyStem® containing CDCs dramatically increases 
cell retention 24 h after delivery when compared 
with cells in PBS. Even in long-term cell engraftment 
(3 weeks after delivery), a significant retention is 
observed. Also, improvements in left ventricular 
ejection fraction and addition of viable myocardial 
mass are demonstrated (Smith et al., 2013). Murugan 
Girija et al. (2018) demonstrated that the expression 
of keratinocyte-specific markers by human pre-
differentiated gingival MSCs is higher when the cells 
are encapsulated in HyStem® as compared with 2D 
culture, showing that HA-based hydrogels provide 
a 3D environment to enhance differentiation.
 Given that HA is a major constituent of the eye, 
HA hydrogels also provide ideal viscous solutions for 
retinal repair in ocular surgery (Durrie et al., 2018). 
HA-based hydrogels are also studied as an injectable 
delivery system of mouse RPCs into subretinal space. 
Transplantation of these HA hydrogels causes very 
little disruption to the host retinal architecture while 
providing a unique microenvironment for self-
renewal and differentiation of RPCs (Liu et al., 2013). 
Liu et al. (2013) studied different systems with varying 
ratios of HyStem® components vs. cells medium and 
amount of Extralink with the purpose of modulating 
the mechanics and degradation time of the hydrogel 
matrix. In this sense, hydrogels with 40 % and 20 % 
HyStem® volume effectively support self-renewal of 
RPCs, while the 80 % HyStem® does not support the 
growth and survival of mouse RPCs probably due 
its higher concentration, which would substantially 
block nutrients and oxygen supply (Liu et al., 2013). 
These cross-linkable HA derivatives degrade over a 
period of 3 weeks, showing greater stability than a 
previous blend of HA and methylcellulose (Ballios et 
al., 2010). However, the bioresorbable hydrogel blend 
of HAMC is also applied as an injectable hydrogel 
delivery strategy to promote cell survival and 
integration of transplanted retinal stem cell-derived 
rods and NSCs in the retina and brain, respectively, 
for functional repair (Ballios et al., 2015). The survival 
effect observed after 3 weeks post-transplantation 
in HAMC versus saline vehicle is attributed to cell-
material interactions through the CD44 receptor, 
since CD44−/− cells do not show increased survival in 
vivo (Ballios et al., 2015). Also, HA is widely used in 
cartilage repair to restore the biologic environment 
of the joint in OA patients. In fact, IA injection of 
HA is considered to be a treatment for early OA, 
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acting as a lubricant in the joint space in order to 
reduce pain by reducing the friction of the joint 
and improving viscoelasticity of the synovial fluid 
(Campbell et al., 2015; Concoff et al., 2017). There are 
different commercial preparations based on HA for 
viscosupplementation by IA injections (Jones et al., 
2018). These products differ in their composition, 
molecular weight, average life in the joint and price 
(Altman et al., 2016; Estades-Rubio et al., 2017).
 Non-surgical IA orthobiologic injectables to treat 
OA also include PRP, a blood-derived product rich in 
growth factors. PRP can enhance production of ECM, 
inhibit inflammation and display beneficial effects 
on cartilage regeneration (Cengiz et al., 2018; Wu 
et al., 2011). In a recent study conducted by Filardo 
et al. (2015), the efficacy of IA injections of high-
molecular-weight HA (Hyalubrix®, Fidia Pharma 
USA) versus the use of PRP for the treatment of knee 
cartilage degenerative lesions and OA was compared. 
Although preliminary results suggest that PRP 
injections might offer a clinical improvement, both 
treatments decrease the pain in knee of OA patients 
but the data are not statistically significant (Filardo 
et al., 2015). Recent studies still disagree on which 
of the two strategies is most beneficial for patients 
(Dai et al., 2017; Ye et al., 2018; Zhang et al., 2018). 
Moreover, others have proposed the development of 
a new formulation combining HA and PRP to achieve 
a more effective treatment for OA (Andia and Abate, 
2014; Chen et al., 2014; Lana et al., 2016; Russo et al., 
2016). This combination is based on the fact that, on 
one hand, PRP could provide growth factors that 
may modify gene expression of OA chondrocytes and 
enhance the anabolic activity of chondrocytes while, 
on the other hand, HA may reduce pain and provide 
the viscosupplementation needed for OA treatment. 
Russo et al. (2016) studied the combination of PRP 
with different HA formulations (Sinovial® 0.8% ; 
Sinovial Forte® 1.6%; Sinovial HL® 3.2%; Hyalubrix® 
1.5%, Fidia Pharma USA) in order to evaluate their in 
vitro biological effect on osteoarthritic chondrocytes 
and which HA formulations are more suitable 
to use in combination with PRP. Their results 
demonstrate that viscosupplements containing low 
HA concentration are not indicated for combination 
with PRP, as the viscoelastic properties are lost. 
In all cases, the chondrocyte GAG content and 
proliferation rate are higher in media containing PRP 
and HA formulations than in media containing only 
HA formulations. Interestingly, although Sinovial 
Forte®, Sinovial HL® and Hyalubrix® present the 
same rheological profile, Sinovial HL® is superior in 
stimulating GAG production (Russo et al., 2016).
 In addition to HA and PRP, a third-generation of 
IA injection therapy using BMC has emerged with 
the aim of retarding the progressive destruction of 
Fig. 7. Intra-articular injections of HA. Intra-articular injections of HA are widely used as a lubricant in 
the joint space for the treatment of knee OA pain. In recent years, stem cell injections have been used in 
combination with HA for cartilage tissue regeneration.
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cartilage (Sampson et al., 2013). The development 
of articular stem cell therapies is promising, since 
these cells have the ability for self-renewal and 
differentiation into osteogenic or chondrogenic 
lineages (Canadas et al., 2018). HA injection therapies, 
combined with MSCs from BM, are currently 
under investigation for bone and cartilage tissue 
regeneration (Kaleka et al., 2018; Roffi et al., 2018), (Fig. 
7). Indeed, BMC injections are used in combination 
with HA and fibrin, a protein scaffold with the natural 
ability to change phase from liquid to gel by addition 
of thrombin (Huh et al., 2016). Therefore, fibrin is 
used with HA to promote retention of BMC at the 
injected site, forming a polymer composite within 
a few minutes after being injected. The mixture 
injected, following a microfracture procedure, can 
induce chondrogenesis in vivo and represents a novel 
strategy for treatment of chondral defects (Huh et al., 
2016).
 In addition to BM stem cells, recent in vivo 
studies in small and large animal models have tested 
hydrogel composites of human UCB-MSCs mixed 
with 4 % sodium hyaluronate. These formulations 
show an improvement in the histologic appearance 
of the repaired articular cartilage tissue, which could 
represent a stepping stone to future human clinical 
trials (Ha et al., 2015; Park et al., 2015). Moreover, since 
stem cells possess the capacity to migrate to the site of 
injury, HA hydrogels combined with drugs or growth 
factors were developed in order to guide endogenous 
stem cells towards a specific site or injured area 
and to promote the regeneration of the tissue (Jha 
et al., 2015). The slow release of rSDF-1α inside of a 
crosslinked HA hydrogel significantly increases BMC 
chemotaxis in vitro and improves cell engraftment 
and BMC homing to the remodelling myocardium 
better than the delivery of rSDF-1α alone following 
experimental MI (Purcell et al., 2012). The engineered 
HA hydrogel is formed in situ through photoinitiated 
radical polymerisation using a HA derivative 
previously esterified with HEMA. The hydrolysis of 
the ester bonds between the HA backbone and the 
methacrylate groups allows slow degradation of the 
hydrogel and subsequent release of rSDF-1α (Purcell 
et al., 2012). In a different study, HyStem®-C hydrogel 
is used to load BDNF, which is delivered in the brain 
following distal middle cerebral artery occlusion. 6 to 
8 weeks after implantation, improved sensorimotor 
function is observed in treated rats and infarct volume 
is reduced, suggesting that targeted intracerebral 
delivery of BDNF using this hydrogel may mitigate 
ischaemic brain injury and restore functional deficits 
by reducing neuroinflammation (Ravina et al., 2018).
 Another appreciated function of HA comprises its 
use as a system for molecule delivery (Fig. 8). CD44, 
is highly expressed in articular cells, particularly 
chondrocytes (Ishida et al., 1997); therefore, based 
on the binding property of CD44 with its ligand HA, 
the development of HA-coated nanoparticles for 
drug delivery has been investigated. Nanoparticles 
Fig. 8. HA-modified nanoparticles are easily internalised by CD44+ cell. The CD44 receptor present on 
the surface of articular cells, particularly of chondrocytes, mediates internalisation of the nanoparticles 
that can be loaded with therapeutics agents or complexed with genes for regenerative medicine strategies.
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of several synthetic polymers, such as PLA or PLGA, 
are covered with HA in order to allow for sustained 
drug delivery in the vicinity of the joint and to achieve 
high drug concentrations at the site of action for 
the treatment of arthritis and/or OA (Laroui et al., 
2007; Zille et al., 2010). Moreover, the potential role 
for HA in gene therapy strategies has been tested 
by the formulation of HA nanoparticles as delivery 
systems for plasmid DNA. For example, hybrid HA/
chitosan nanoparticles were developed as novel non-
viral gene delivery vectors capable of transferring 
exogenous genes into primary chondrocytes for 
the treatment of joint diseases (Lu et al., 2011). 
Indeed, higher chondrocyte transfection efficiency 
of nanoparticles containing HA/chitosan and pDNA 
encoding TGF-β1 is observed as compared to the 
same nanoparticles without HA (Lu et al., 2013). In 
addition, the formulation of a novel HA hydrogel as 
a delivery system for the controlled release of gapmer 
antisense oligonucleotides for unassisted cellular 
entry and subsequent gene silencing activity was also 
investigated for cartilage repair and interruption of 
damage progression by Cai et al. (2017).
 HA was also studied in the treatment of 
different pathologies in which the immune system 
is deregulated, such as DM, RA and Sjögren 
Fig. 9. Therapeutic applications of HA-based scaffolds in organ-specific TE and regenerative medicine. 
HA-based scaffolds are a key component for biomedicine applications such as the healing and regeneration 
of cartilage, bone, skin, nervous, cardiac and lung tissue and eye surgery.
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syndrome, among others. CD44 is expressed 
by numerous immune cell types (lymphocytes, 
neutrophils, macrophages, natural kill cells, etc.) 
and the interaction of HA with CD44 favours the 
activation and migration of these cells towards the 
inflamed injury, with HA interacting with cytokines 
and modulating the immune responses (Zamboni 
et al., 2018; Zamboni and Collins, 2017). Nakamura 
et al. (2004) showed, in a mouse liver injury model, 
that high molecular weight HA has intrinsic anti-
inflammatory properties since HA-CD44 binding 
can inhibit the production of proinflammatory 
cytokines. Rho et al. (2018) showed that HA-based 
nanoparticles can suppress the inflammation of the 
adipose tissue in type 2 DM because of a decrease in 
both macrophages and proinflammatory cytokines. 
In addition, these nanoparticles can inhibit the 
domain-containing protein 3 inflammasome activity, 
causing an improvement in insulin sensitivity and 
normalised blood glucose levels (Rho et al., 2018). 
RA is a chronic autoimmune disorder that results 
in systemic autoimmune destruction of bone and 
cartilage. In the treatment of the pathology, HA 
administered together with solid lipid nanoparticles 
can improve the vehiculation of different drugs (i.e. 
glucocorticoids) to inflammatory cells (through 
binding to CD44+ cells), facilitating the selective release 
of these drugs in inflamed tissues (Zhou et al., 2018). 
Dry eye disease is the main clinical manifestation of 
Sjögren syndrome, a chronic inflammatory disease 
with an autoimmune basis (Stefanski et al., 2017). HA 
is administered as a substitute for tears and it acts 
on the ocular surface, increasing its hydrophilicity 
and density and reducing the surface tension while 
favouring the contact time on the cornea and, thereby, 
the hydration of the eye (Cagini et al., 2017).
Applications in TE
Another promising area of regenerative medicine 
in which HA is making a significant contribution is 
TE. In fact, HA-based scaffolds are widely used in 
the regeneration of tissues such as cartilage, bone, 
skin, nerve tissue and cardiac tissue (Hemshekhar et 
al., 2016) (Fig. 9).
Cartilage and bone TE
There is an increasing interest in the study of 
HA-based 3D scaffolds for cartilage and bone TE 
(Bowman et al., 2018). HA has been used for cell 
encapsulation of hESC-derived chondrogenic cells. 
Toh et al. (2010) created a cell-engineered cartilage 
by mixing the cells with HyStem® matrix. This 
artificial ECM was investigated in an osteochondral 
defect rat model showing a complete integration 
with the adjacent host cartilage, with no evidence 
of tumorigenicity, and generating an ECM similar 
to the native cartilage tissue (Toh et al., 2010). The 
concentration of HA is a determining factor in the 
production of hyaline cartilage, since it is directly 
related to expression of chondrogenic genes, 
production of GAGs and suppression of fibrocartilage 
production (Zhu et al., 2017). Erickson et al., (2012) 
established that lower concentrations (1 % w/vol) 
of crosslinked HA hydrogels increase MSC seeding 
density more than hydrogels at 3 % or 5 % w/
vol concentrations. These hydrogels formed by a 
photocrosslink reaction of a MeHA derivative are 
highly appropriate to form ECM and to reproduce 
the native cartilage tissue properties (Erickson et al., 
2012). An additional advantage of HA for cartilage 
regeneration is related to its release ability. As shown 
by Deng et al. (2019), the incorporation of HA to PLA/
PEG/PLA hydrogels favours a controlled release of 
TGF-β3, which improves chondrogenesis both in 
vitro and in vivo.
 For bone regeneration, several scaffolds have 
been created by the combination of HA with other 
polymers with the aim of providing good mechanical 
properties and improving degradation rates. Antunes 
et al. (2010) developed a hybrid scaffold that shows 
great promise for bone tissue applications. HA has 
been used to coat scaffolds produced from PLA and 
to enhance the bio-compatibility and biological cell 
response, joining the best properties of each material. 
3D PLA porous hybrid scaffolds are coated with 
HA, followed by crosslinking with glutaraldehyde, 
to produce biomimetic porous scaffolds for cortical 
bone therapeutic agents. In addition, results derived 
from using fibroblasts show that these scaffolds allow 
cell adhesion, growth and proliferation (Antunes et 
al., 2010). This improvement of mechanical properties 
can also be achieved thanks to the combination of 
different natural materials. Combination of HA 
with nano-hydroxyapatite, chitosan and chondroitin 
sulphate allows obtaining scaffolds that mimic 
both the structure and the composition of natural 
bone, also showing a good biocompatibility (Hu 
et al., 2017). On the other hand, modifications in 
HA, such as sulphation, can induce differentiation 
towards osteoblasts and production of a native bone 
ECM, through synthesis, secretion and/or activity 
of fibrillary or non-fibrillary ECM components, 
including proteases and their inhibitors (Schmidt et 
al., 2018).
Skin TE
Skin substitutes, including acellular matrices, 
cellular substitutes and keratinocyte grafts, must 
meet indispensable characteristics, such as semi-
permeable barrier, cell adhesion, non-toxic, non-
inflammatory, non-immunogenic, durable, malleable 
and biodegradable properties (Nicholas et al., 2016). 
HA combines such characteristics with the ability 
to inhibit tissue adhesion and scar tissue formation 
(Monteiro et al., 2015). Thiolated HA derivatives 
based on the strategy developed by Shu et al. (2002) 
can oxidise in air to form disulphide cross-linked 
HA hydrogels. Following this strategy, commercial 
thiolated carboxymethyl hyaluronic acid or CMHA-S 
(CanitrX® Gel; SentrX®, SentrX™ Animal Care, Inc., 
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Salt Lake City, UT, USA), have been marketed to 
facilitate and accelerate wound healing in dogs. The 
healing process in the presence of these materials 
is slower but at the same time the scar formation is 
minimised (Hadley et al., 2013).
 HA was also combined with decellularised 
extracellular matrix and human peripheral blood 
mononuclear cells for skin wound healing, showing 
regeneration of the epidermis and dermis in the 
wounds created in nude mice (Kuna et al., 2017). 
Moreover, HA can be applied in combination with 
other materials. The incorporation of a photocross-
linkable FN conjugated into HA 3D hydrogel network 
enhances endothelial cell adhesion and angiogenesis 
showing great potential in skin TE (Seidlits et al., 2011). 
Tamer et al. (2018) studied the combination of HA 
with chitosan – a combination that has positive effects 
on healing – while incorporating mitochondrially-
targeted antioxidant-MitoQ (BioAssay Systems, 
Hayward, CA, USA) an element that allows to obtain 
better results, with a faster and more efficient healing, 
and trigger less inflammation in vivo.
 Different examples of commercially available 
products based on HA or its derivatives can be 
found. Hyalomatrix® (Anika Therapeutics, Inc., 
Bedford, England) a non-woven pad made of 
partially esterified HA (HYAFF®), is a dermal 
substitute that acts as a 3D scaffold for cellular 
invasion and capillary growth. This advanced wound 
care device is indicated for the treatment of partial 
to full-thickness post-traumatic, post-surgical or 
deep-chronic wounds, such as vascular ulcers or 
diabetic foot ulcers (Gravante et al., 2010). Membranes 
such as LaserSkin® (Fidia Advanced Biopolymers, 
Padua, Italy), consisting also of HYAFF® but with 
microperforations, are available for treatment of 
chronic, non-healing wounds, allowing successful 
treatment when used in combination with autologous 
or allogenic keratinocytes (Uccioli, 2003).
Nervous TE
HA is a promising material for brain and neural 
regeneration since it is widely present in the central 
nervous system and has the capacity to reduce 
glial scar formation and allow the penetration of 
cells, nerve fibres and blood vessels (Kornev et al., 
2018). Thus, topical applications of a highly purified 
sodium hyaluronate formulation (Orthovisc®, 
Anika Therapeutics, Inc.) on rat transected sciatic 
nerves show a significant reduction in perineural 
scar thickness while, at the same time, promoting 
neural regeneration (Özgenel, 2003). HA hydrazone 
derivatives cross-linked with laminin and ECM 
protein involved in neuronal development and 
survival have been evaluated for in vivo brain lesion 
repair. These hydrogels, once implanted into cortical 
defects created in rats, form a scaffold that support 
cell infiltration and angiogenesis and promote neurite 
extension (Hou et al., 2005).
 HA hydrazone derivatives have also been coupled 
with short cell-adhesive peptides such as RGD and 
IKVAV. These derivatives show similar results to those 
obtained for HA-laminin derivatives, promoting cell 
migration and axonal growth and regeneration (Cui 
et al., 2006; Wei et al., 2007). Furthermore, hydrogels 
made of blends of HA and methylcellulose or 
collagen I can induce neuronal differentiation of 
brain-derived neural stem/progenitor cells (Brännvall 
et al., 2007; Mothe et al., 2013; Valderrábano, 2007).
 In designing engineered tissues such as nerve 
and myocardium, an important consideration is 
the anisotropic structure to accurately mimic the 
structure and function of the native electroactive 
tissue (Kim et al., 2007; Valderrábano, 2007). In this 
context, there has been increasing attention on 
engineering biomaterial scaffolds that are electrically 
conductive. Indeed, several research groups have 
explored the use of conductive polymers to regulate 
cellular response, including DNA synthesis, cell 
adhesion, proliferation, migration and differentiation 
(Jeong et al., 2008; Park et al., 2014; Shi et al., 2008). 
Wang et al. (2017a) used HA to improve the bioactivity 
of the conductive polymer PEDOT, a polythiophene 
derivative. PEDOT-HA conductive nanoparticles are 
synthesised by chemical oxidative polymerisation 
and incorporated into PLLA. PEDOT-HA/PLLA films 
are cultured with neuron-like pheochromocytoma 
(PC12) cells showing better cell adhesion, viability 
and spreading as compared with pure PLLA films. 
Moreover, increased neurite length under electrical 
stimulation as opposed to under no electrical 
stimulation condition is demonstrated. The results 
indicate that the conductive PEDOT-HA/PLLA 
films combined with electrical stimulation may be a 
promising strategy for enhancing nerve regeneration 
in nerve TE (Wang et al., 2017a).
Cardiac TE
TEHV were studied with the aim of creating living, 
non-cytotoxic, mechanically analogous heart valve 
replacements that can grow and remodel with the 
patient (Masoumi et al., 2014; Sanz-Garcia et al., 
2015). VICs are the most prevalent cell type in aortic 
heart valves and these cells have been utilised to 
engineer functional TEHV (Mahler and Butcher, 
2011; Masoumi et al., 2014). VICs can enhance ECM 
production on photopolymerisable hydrogels 
formed from 2 % MeHA solution, proving that HA 
can stimulate heart valve tissue formation (Masters 
et al., 2004). Additionally, scaffold degradation 
products increase VICs cell viability and induce 
proliferation and matrix synthesis after 6 weeks in 
culture (Masters et al., 2005). Hybrid meshes that 
blend HA with PCL support cell adhesion and 
proliferation over the entire construct and formation 
of primitive capillary network (Ekaputra et al., 2011; 
Eslami et al., 2014). Moreover, acellular HA-based 
hydrogels reduce stress in the heart wall after MI 
(Ifkovits et al., 2010). Ifkovits et al. (2010) described 
how mechanical properties of HA hydrogels are 
modified through a simple alteration in the number of 
reactive methacrylate groups on the MeHA polymer: 
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30 % (MeHA low) versus 60 % (MeHA high). The 
two MeHA formulations exhibit similar degradation 
and tissue distribution upon injection but have 
different storage modulus (~ 8 kPa versus ~ 43 kPa). 
Moreover, only the higher-modulus (MeHA high) 
treatment group show a statistically smaller infarct 
area as compared with the control infarct group when 
injected into a clinically ovine MI model (Ifkovits et 
al., 2010). Taken together, these studies indicate that 
HA matrices represent a good choice to promote 
cardiovascular regeneration.
Other tissues in TE
Space-filling HA-based scaffolds provide bulking, 
prevent adhesions, excessive scar formation or 
function as bio-adhesives after surgical procedures 
or injury. Hyaloglide® (Anika Therapeutics, Inc.) is an 
auto-cross-linked HA derivative that forms a highly 
viscous gel. About 5 % of the HA carboxyl groups 
are activated to promote the cross-linking reaction 
by nucleophilic attack of the GluNAc unit primary 
hydroxyl groups to form an esterified cross-linked 
HA (Atzei et al., 2007). This HA derivative, approved 
for clinical use, shows a reduction of pain and a major 
recovery of sensitivity after tendon and peripheral 
nerve surgery (Atzei et al., 2007; Pederzini et al., 2013).
 Several studies have opened new avenues towards 
the use of HA-based scaffolds for TE. Espandar et al. 
(2012) showed the in vivo growth of human adipose 
stem cells on HyStem® matrix, with cells surviving 
and expressing human-cornea specific proteins. For 
lung tissue regeneration, Radhakumary et al. (2011) 
developed a copolymer of HA-poly HEMA that is 
non-cytotoxic to mammalian cells. Further, this co-
polymer hydrogel supports alveolar cell adhesion 
and growth and is suitable for the adhesion and 
proliferation of multiple cell types (Radhakumary 
et al., 2011). For meniscal regeneration, MSCs in a 
hyaluronan-collagen scaffold display good healing 
potential with the development of integrated 
meniscus-like repair tissue (Murphy et al., 2018). 
Furthermore, the implantation of eEPCs encapsulated 
in HyStem® matrix demonstrates improved resistance 
to toxic insult (adriamycin) in vitro, eEPC mobilisation 
to injured kidneys and improved renal function 
(Ratliff et al., 2010).
Clinical applications of HA with cells and tissues
Cell therapies and TE remain very active areas of 
research, which have been translated to clinical trials 
at an extraordinary pace recently (Gálvez-Martín et 
al., 2017). Currently, from a total of 6,085 clinical trials 
with stem cells being carried out worldwide, 16 assess 
the efficacy and safety of stem cells in combination 
with HA for different therapeutic applications, most 
of which focus on OA and cartilage regeneration 
(Table 1a,b). Moreover, HA viscosupplementation 
is a popular treatment option in the non-operative 
management of patients with OA; HA is also used 
in many studies as an active control to compare the 
efficacy of stem cell transplantation in many OA 
treatments (Web ref. 1-6). The increasing use of HA 
in combination with cells in current clinical trials 
usually responds to the need of improving delivery 
methods and enhancing survival and retention of 
cells in vivo. Randomised controlled trials have been 
successfully carried out and are currently evaluating 
an optimal stem cell source, together with HA 
for therapeutic repair of cartilage tissue. In one of 
these clinical studies, Saw et al. (2013) transplanted 
autologous PBSCs in combination with HA into 
an articular cartilage defect by IA injections after 
arthroscopic subchondral drilling. This resulted in 
an improvement of the quality of articular cartilage 
repair when compared with the same treatment 
with injections of HA alone (Saw et al., 2013; Web 
ref. 7). A similar study using PBSCs and HA is 
currently recruiting patients (Web ref. 8). Attempts to 
regenerate cartilage have also been made using MSCs 
originating from the BM. In a recent multicentre 
randomised clinical trial, IA delivery of increasing 
doses of BM-MSCs in combination with HA sodium 
salt (1,500-2,000 kDa; Hyalone®, Fidia Farmaceutici 
S.p.A., Abano Terme, Italy) has been evaluated (Web 
ref. 9). Both treatments, HA alone or with low-dose 
BM-MSCs (10 × 106), can reduce pain in the first 
6 months; however, patients receiving the high-dose 
of BM-MSCs (100 × 106) together with HA exhibit an 
improvement in their perception of pain in their daily 
activity after 12 months as compared to HA alone 
(Emadedin et al., 2012). The study demonstrated 
that the single IA injection of in-vitro-expanded 
autologous BM-MSCs together with HA is a safe and 
feasible procedure, which results in a clinical and 
functional improvement of knee OA (Lamo-Espinosa 
et al., 2016). Recently, the long-term results of this 
clinical trial have been published confirming the 
safety of the procedure and a functional improvement 
of knee OA after a follow up of 4 years. However, 
long-term results show no clinical differences 
between low-dose and high-dose groups and the 
authors’ question if a high dose of cells is needed. 
Additionally, the control group receiving only HA 
initially perceives pain reduction and improvement of 
physical function subscores but these improvements 
are not sustained after a long-term follow up. In any 
case, these results support the development of future 
phase III clinical trial (Lamo-Espinosa et al., 2018). 
Similarly, another clinical trial aims at determining 
the efficacy of single IA implantation of autologous 
BM-MSCs in a high molecular weight injectable 
HA (Orthovisc®, Anika Therapeutics, Inc.) for the 
treatment of patients with mild to moderate OA: HA 
is used as an active comparator and the objective is 
to elucidate if IA implantation of autologous BMSCs 
in patients with mild to moderate OA can regenerate 
damaged cartilage (Web ref. 10). In another study, 
Stempeucel® (Stempeutics Research Pvt. Ltd., 
Bangalore, India), which consists of a cryopreserved 
stem cell product containing allogeneic MSCs 
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Table 1a. Clinical trials with HA and stem cells.
NTC number Phase Indication Intervention Purpose Cell type
NCT01076673 II
Articular 
cartilage 
disorder of 
knee
IA injections of PBSCs and HA
To compare articular cartilage 
regeneration in patients with 
chondral lesions treated by 
arthroscopic subchondral drilling 
followed by postoperative IA 
injections of HA with and
without PBSCs
PBSCs
NCT02123368 I/II OA
IA injection of BM-MSCs (dose 
groups: 10 and 100 million cells) 
cultured ex vivo followed by an IA 
injection of HA (Hyalone®)
To determine the safety, 
feasibility and effectiveness of IA 
administration of different doses 
of BM-MSCs in combination
with HA
Autologous 
BM-MSCs
NCT01459640 II OA
Single IA implantation of
BM-MSCs in 30 mg/2 mL of HA 
(Orthovisc®)
To determine the efficacy of IA 
implantation of autologous BM-
MSCs for treatment of patients 
with mild to moderate OA
Autologous
 BM- MSCs
NCT01453738 II Knee OA
Single IA dose of Stempeucel® 
(dose groups: 25, 50, 75 and 
150 million cells) followed by 
2 mL of HA (20 mg)
To evaluate the safety, potential 
efficacy and appropriate dose of 
IA administration of Stempeucel® 
followed by HA in patients with 
OA of the knee joint
Allogeneic
BM- MSCs
NCT00225095 I/II
Recovery 
following 
partial medial 
meniscectom
IA injection of ChondrogenTM, a 
preparation of BM-MSCs (dose 
goups: 50 and 150 million cells) 
suspended in 2 mL (20 mg) of 
sodium hyaluronate, human 
serum albumin (1.2 %) and 
PlasmaLyte A
To determine whether 
ChondrogenTM is a safe and 
effective post-operative 
treatment of the knee following 
menisectomy
Allogenic
BM-MSCs
NCT02659215 N/P
Defect of 
articular 
cartilage
2 mL of BMAC loaded per 
Hyalofast® scaffold (a benzyl ester 
of HA) and, then, implanted to 
cover the defect
To evaluate the efficiency of 
Hyalofast® together with BMAC, 
in a one-step arthroscopic 
procedure as compared to 
microfracture in the treatment of 
symptomatic cartilage
defects of the knee
BMAC
NCT01088191 I/II
Anterior 
cruciate 
ligament 
injury, OA
Single injection into the knee 
joint of two different single doses 
of MSB-CAR001 (mesenchymal 
precursor cells, Mesoblast, Ltd) 
combined with HA
To evaluate safety and efficacy 
of MSB-CAR001 in subjects who 
have undergone an anterior 
cruciate ligament reconstruction 
since short time
Allogeneic
 MPCs
NCT01290367 II
Degenerative 
disc disease
Injection of MPCs (dose groups: 
6 and 18 million cells) in a HA 
carrier into the degenerated 
lumbar disc’s nucleus pulposus
To compare two doses of 
immunoselected, allogeneic 
MPCs when combined in a HA 
carrier in subjects with chronic 
lower back pain due to moderate 
degenerative disc disease
Allogeneic
 MPCs
NCT02412735 III
Degenerative 
disc disease
Injection into the painful IVD of 
Rexlemestrocel-L (dose: 2 mL of 
6 million cells) alone or combined 
with 1 % HA
To evaluate the safety and efficacy 
of Mesoblast’s Rexlemestrocel-L 
alone or combined with HA in 
subjects with chronic lower
back pain
Allogeneic
 MPCs
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Table 1b. Clinical trials with HA and stem cells.
NTC number Phase Indication Intervention Purpose Cell type
NCT02338271 I Lower back pain
A single injection into the centre 
of the nucleus pulposus of 
adipose-derived MSCs (dose 
group: 2 × 107 and 4 × 107 cells/
mL/vial) plus Tissuefill®
1 mL/syringe
To evaluate safety and efficacy 
of autologous adipose-derived 
MSC implantation in chronic 
lower back pain patients with 
lumbar IVD degeneration
Autologous
adipose-
derived MSCs
NCT01733186 I/II
Degeneration of
articular knee
cartilage 
Single-dose of 0.5 mL of 
Cartistem® (UCB-MSCs 
combined with sodium 
hyaluronate) per cm2 of 
cartilage defect
To determine the safety and 
efficacy of Cartistem® in the 
treatment of articular cartilage 
defects of the knee as a result of 
ageing, trauma or degenerative 
diseases
UCB-MSCs
NCT02755376 N/P
Injuries of anterior 
cruciate ligament
Single-dose of Cartistem®,
a combination of human UCB-
MSCs and sodium hyaluronate
To evaluate enhancement of 
healing of anterior cruciate 
ligament injury using
UCB-MSCs
UCB-MSCs
NCT02034786 I
Lipodystro-
phies,aesthetics 
procedure
Transdermal injection of a 
filler agent composed of MSCs 
from autologous adipose tissue 
associated with HA
To study the efficacy and safety 
of transplantation of autologous 
adipose stem cells with HA for 
the treatment of lipodystrophy
Autologous
MSCs from
adipose tissue
NCT02698813 I
Senescence 
wrinkles, acne, 
pitting scar
Transdermal injection of 
UC-MSCs and HA
To evaluate the safety and 
efficacy of the injectable filler 
agent composed of UC-MSCs 
and HA for the improvement of 
wrinkles, acne and pitting scar
UC-MSCs
NCT01981330 I
Severe hoarseness 
and vocal fold 
scarring
Single injection of BM-MSCs 
mixed with a carrier
hyaluronan gel
To evaluate the efficacy of the 
injection of BM-MSCs mixed 
with and without hyaluronan 
gel to heal scarred vocal folds
Autologous
BM-MSCs
NCT03101163 II
Degeneration 
and disorder of 
articular knee 
cartilage 
IA injections of PBSCs and HA 
To evaluate and determine 
whether PBSCs with HA 
therapy can improve functional 
outcome and reduce pain of the 
knee joint better than a
standard treatment
Autologous
PBSCs
from multiple BM donors, has been tested together 
with HA in order to increase the engraftment and 
chondrogenic activity. In the preclinical model of 
OA, Stempeucel®, at both low and high doses and 
supplemented with  HA, significantly reduces pain 
and repairs damaged articular cartilage in rats (Gupta 
et al., 2016). In the clinical study, IA administration of 
Stempeucel® followed by injection of HA appears to 
be safe, showing a trend towards improvement in all 
subjective parameters (VAS, ICOAP and WOMAC-
OA scores) in the low-dose group. However, when 
compared to a placebo (Plasmalyte-A, Baxter 
Healthcare Ltd., Norfolk, England) no therapeutic 
efficacy is observed, which the authors attribute to 
the small number of patients enrolled in the study. 
Another drawback observed in the study is that 
the treatment with higher dose groups (50, 75 and 
150 × 106 cells) causes knee pain and swelling (Gupta 
et al., 2016; Web ref. 11).
HA together with MSCs tested for meniscus repair
In a double-blind clinical study with Chondrogen® 
(Osiris Therapeutics, Baltimore, MD, USA) a 
preparation of adult MSCs in a solution containing 
HA shows that a single injection of Chondrogen® into 
the knee of patients following partial meniscectomy 
can significantly increase meniscal volume and 
reduce knee pain as compared with the use of HA 
alone, when measured 12 months post meniscectomy 
(Web ref. 12). Patients with osteoarthritic changes 
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at the time of surgery experience a reduction in 
pain following the treatment due to HA – which is 
a commonly used treatment for OA pain (Concoff 
et al., 2017) possibly providing some benefit to the 
patients (Vangsness et al., 2014). These studies help to 
elucidate the role of MSCs in knee-tissue regeneration 
and to increase the potential of HA in cell therapy. 
The use of HA-based scaffolds loaded with cells 
that fit the cartilage lesion is the promising strategy 
of a clinical trial currently recruiting participants to 
evaluate the safety and efficacy of Hyalofast® (Anika 
Therapeutics, Inc.), a biodegradable hyaluronan-
based (HYAFF®) scaffold, and BMAC in the treatment 
of cartilage defects of the knee. The purpose of the 
study is to evaluate the efficacy of a Hyalofast® 
scaffold, which acts as a biodegradable support for 
the autologous BMAC and to compare this treatment 
to microfracture, an arthroscopic surgical technique 
providing stem cells and growth factors from the 
BM to aid cartilage repair (Web ref. 13). Cavallo et al. 
(2013) demonstrated in vitro that BMCs grown onto 
HYAFF®-11 can differentiate into chondrogenic cells 
by expressing and producing specific ECM molecules. 
Additionally, a previous study with 20 patients 
older than 45 years demonstrated the safety and 
efficiency of treating full thickness cartilage lesions 
with Hyalofast® soaked in BMACs, showing that 
indication to surgery should not be based only on 
age, but rather on lesion size and number. However, 
a long-term comparative study with a larger sample 
and with a detailed radiological analysis is still 
needed to ultimately assess the potential of this 
technique (Gobbi et al., 2017).
 Another product, consisting of immune-selected 
allogenic MPCs derived from adult BM, is being 
tested in combination with HA and HA alone as 
an active comparator for the treatment of anterior 
cruciate ligament injury (Web ref. 14), degenerative 
disc disease (Web ref. 15) and is currently recruiting 
participants with chronic lower back pain for a new 
phase III study (Web ref. 16). Preliminary results 
from the anterior cruciate ligament injury study 
showed that IA administration of MPCs is safe and 
well tolerated, both MPCs + HA- and HA-injected 
groups show symptomatic improvement; however, 
the MPC + HA-treated group exhibits larger changes 
from baseline (Wang et al., 2017b).
 The implantation of autologous MSCs from 
adipose tissue was tested in combination with a 
medical fill composed of an HA gel cross-linked with 
butanediol diglycidyl ether (Tissuefill® NeoGenesis 
Co., Ltd., Seoul, Korea) as a cell carrier in patients 
with chronic lower back pain caused by lumbar 
disc degeneration (Web ref. 17). Ahn et al. (2015) 
showed that co-administration with Tissuefill® can 
enhance the efficacy of intradiscally injected MSCs. 
The results from the phase I clinical trial confirm the 
safety and tolerability of co-injection of MSCs and 
the HA derivative in patients with IVD degeneration. 
Significant improvements in pain are demonstrated 
in 6 out of 10 patients and rehydration of the disc in 
3 out of 6 patients throughout the 12-month duration. 
The exact mechanism by which the combined 
implantation of MSCs and the HA derivative leads to 
improvement of chronic discogenic lower back pain 
remains unclear, however, the authors assume that 
injection of MSCs into the degenerated disc improves 
ECM production by the degenerated host nucleus 
pulposus cells and modulates their immunological 
response to inflammatory cytokines that could 
potentially inhibit the inflammatory cascade, thereby 
preventing ingrowth of pain-inducing vasculature 
and nerve fibres. On the other hand, suspension of 
the cells in HA derivative for coadministration may 
prevent cell leakage, reduce the risk of uncontrolled 
differentiation of MSCs into osteoblasts and enhance 
cell attachment and cell survival (Kumar et al., 2017).
 Among the few MSC-based products that 
are approved worldwide, one combines sodium 
hyaluronate with human UC-MSCs. Cartistem® 
(Medipost Co., Ltd, Bundang-gu, Korea) has been 
approved for sale in Korea by the Korean FDA since 
January 2012 and is intended to be used as a single-
dose therapeutic agent for cartilage regeneration 
in cartilage defects of the knee. Currently, there is 
an ongoing clinical study to assess the efficacy of 
Cartistem® in articular cartilage defects (Web ref. 18) 
and another one for the healing of the anterior cruciate 
ligament injury (Web ref. 19). Results from phase I/II 
clinical trial in a small sample size (n = 7) investigating 
this product for the regeneration of articular cartilage 
defects in OA patients show an acceptable efficacy 
and safety profile due to improvements in pain and 
function at 24 weeks post-transplantation that are 
maintained without significant deterioration up to 
7 years. The repair site is restored with hyaline-like 
cartilage tissue, which seems to contribute to the 
observed persistence of the regenerated cartilage with 
durable improvement in pain and function (Park et 
al., 2017).
 As a biocompatible filler agent, HA has been 
used for over 25 years for cosmetic purposes and for 
reconstruction of soft tissues. Transdermal injection 
of HA in combination with autologous MSCs 
from adipose tissue is currently being evaluated 
for treatment of lipoatrophy, lipodystrophy types 
characterised by subcutaneous adipose tissue atrophy 
due to trauma, tumour resection and congenital 
defects. The objective is to evaluate if this combination 
is more effective in tissue reconstitution, providing 
volume and cell differentiation and increased 
production of ECM than the injection of adipose tissue 
only (Web ref. 20). In this light, another randomised 
study will be open for participant recruitment in order 
to evaluate the safety and efficacy of the transdermal 
injection of a filler agent composed of UC-MSCs and 
HA for the improvement of wrinkles, acne and pitting 
scar; injection of HA only will be used as an active 
comparator (Web ref. 21). The healing of vocal fold 
scarring, to treat severe hoarseness and vocal fold 
scarring, is also being tested in an ongoing clinical 
trial using a single injection of autologous MSCs from 
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BM alone or MSCs mixed with hyaluronan gel as a 
carrier into the vocal folds (Web ref. 22).
Conclusions and future perspectives
Several chemical strategies have been developed to 
modulate the HA mechanical, chemical and biological 
properties with the objective of broadening HA 
usefulness in cell therapy and TE. Moreover, there 
are increasing clinical trials based on the combination 
of stem cells with HA or HA derivatives. These 
facts unequivocally show the virtues of using HA 
derivatives for in vitro or in vivo applications, alone 
or in combination with cells.
 HA chains present several sites amenable to 
chemical modification, leading to the development 
of a wide array of derivatives aiming to reproduce 
the native tissue properties. Novel formulations 
that improve safety of HA crosslinking in situ 
and prolonged residence time are one of the main 
issues. To improve mechanical properties of HA 
hydrogels, concentrations of crosslinked HA have 
been modulated, opening the way to scaffolds with 
tuneable degradation rate adapted to the tissue of 
the injury. Moreover, with the aim to provide good 
mechanical properties, scaffolds are being created by 
the combination of HA with other polymers.
 New strategies to enhance the bio-compatibility 
and biological cell response include combination 
of HA with materials such as fibronectin, laminin 
or small peptides, among others. In particular, 
decellularised tissue is a promising material that 
can be processed together with HA to produce a gel 
to provide mechanical, biophysical and biochemical 
cues to cells. Furthermore, the current state of 
research has emphasised on the use of HA hydrogels 
combined with drugs, plasmids or growth factors 
to guide endogenous stem cells towards a specific 
injured area or/and promote tissue regeneration. The 
possibility of administering or growing stem cells 
in scaffolds or hydrogels made of HA has created 
high expectations in this field, allowing in vivo cell 
differentiation after a surgical implant.
 Towards next generation products,  the 
functionalisation of conductive polymers by 
incorporating HA for enhancing their physicochemical 
and biological functionality may provide new 
anisotropic scaffolds to mimic the structure and 
function of native electroactive tissue. Currently, new 
preparations based on HA for viscosupplementation, 
including the combination of HA or its derivatives 
with PRP or MSCs derived from BMC, may offer an 
advanced treatment for regeneration, in particular 
of cartilage tissue, that could potentially provide 
better functional outcomes. Moreover, clinical 
trials are focussing on evaluating the efficacy and 
safety of stem cells together with HA formulations. 
Preliminary results, mainly directed to cartilage 
and skin regeneration or restoration, show that 
combination of HA and stem cells is safe and 
improves pain reduction and therapeutic efficacy by 
enhancing cell survival and tissue restoration.
 Finally, novel techniques have also been employed 
towards fabricating HA-based scaffolds. The 
development of 3D bioprinting technologies have 
emerged as a powerful tool for TE due to the 
ability to mimic the 3D structure of any tissue. So, 
the combinations of HA-based bioinks, cells and 
biomaterials will allow obtaining mimetic tissues 
with similar characteristic to native ones and will 
accelerate the clinical application of that technology.
 The development of new HA-based functionalised 
scaffolds and the use of HA or HA derivatives 
as bioinks that mimic ECM for 3D bioprinting in 
combination with different materials and cells are 
issues that will be the focus of future research for 
regenerative medicine purposes. It is expected that 
clinical translation of stem-cells-HA-based therapies 
will be a reality in the next few years.
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Discussion with Reviewer
Declan Devine: The authors illustrated a wide 
range of uses for HA. However, since native bone is 
a composite material, would HA be an appropriate 
matrix material for use in orthopaedic composites?
Authors: HA is an ideal material for natural scaffolds 
thanks to its unique biocompatibility, chemical 
functionalisation and degradability. Several studies 
have suggested that HA-containing scaffold materials 
are efficacious in bone-repair processes (Faruq et al., 
2017; Hamlet et al., 2017; Hu et al., 2017; Turnbull et al., 
2018, additional references). These studies assessed 
the utility of injectable HA gels for the treatment of 
bone-related diseases due to the involvement of HA 
in several biological processes, such as osteoinduction 
and wound healing (Suzuki et al., 2014, additional 
reference). Due to the strong effects of HA on cell 
motility and cell-cell interactions and with the aim of 
improving tissue-scaffold interactions, other studies 
have explored the possibility of developing scaffold 
made of bioceramics and biopolymer, such as HA, 
resulting in the formation of composites for bone 
regeneration (Nguyen and Lee, 2014; Poldervaart 
et al., 2017, additional references). In addition, 
the bone scaffold surface coating with HA is very 
effective in enhancing osteogenesis (Kang et al., 
2011; Motamedian et al., 2015, additional references). 
Finally, regarding orthopaedic materials, HA and 
some of its composites offer a well-established long-
term safety profile and a proven ability to reduce 
bacterial adhesion and biofilm formation on to the 
surface of various biomaterials commonly used in 
orthopaedics, trauma and dental surgery (Romanò 
et al., 2017, additional reference).
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